SQZ Biotechnologies Reports Second Quarter 2023 Financial Re

Phase 1 SQZ-AAC-HPV-101 Clinical Trial Observed a Confirmed Complete Response in the First Patient and a Best Overall Response of Stable Disease in Two Additional Patients in the Lowest-Dose Cohort; Anticipate Interim Data in the Fourth Quarter of 2023SQZ® eAPC Phase 1/2 Trial Monotherapy Enrollment Complete; Antici...

Related Keywords

Howard Bernstein , Programs For Partnership , Company Actively Exploring Strategic Partnerships , Biotechnologies Company , Company Annual Report On Form , Exchange Commission , Management Team , Trial Observed , Confirmed Complete Response , First Patient , Best Overall Response , Stable Disease , Two Additional Patients , Lowest Dose Cohort , Anticipate Interim Data , Fourth Quarter , Third Quarter , Interim Chief Executive Officer , Recent Portfolio , Activating Antigen Carriers , Enhanced Antigen Presenting Cell , Cell Squeeze , Private Securities Litigation Reform Act , Care Manufacturing , Annual Report , Consolidated Statements ,